Production (Stage)
Caris Life Sciences, Inc.
CAI
NASDAQ
Recommendation
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 120.92M | 80.68M | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 120.92M | 80.68M | |||
| Cost of Revenue | 62.21M | 52.62M | |||
| Gross Profit | 58.71M | 28.06M | |||
| SG&A Expenses | 96.01M | 88.03M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 178.87M | 172.90M | |||
| Operating Income | -57.95M | -92.23M | |||
| Income Before Tax | -102.58M | -111.03M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -102.58M | -111.03M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -102.58M | -111.03M | |||
| EBIT | -57.95M | -92.23M | |||
| EBITDA | -50.91M | -74.52M | |||
| EPS Basic | -0.89 | -0.95 | |||
| Normalized Basic EPS | -0.45 | -0.49 | |||
| EPS Diluted | -0.89 | -0.95 | |||
| Normalized Diluted EPS | -0.45 | -0.49 | |||
| Average Basic Shares Outstanding | 142.49M | 141.25M | |||
| Average Diluted Shares Outstanding | 142.49M | 141.25M | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||